




REVIEW

Unraveling Berberine's Molecular Mechanisms in Neuroprotection Against Neurodegeneration

Md. Zamshed Alam Begh , Md Al Amin, Mst Maharunnasa Shatu, Sherouk Hussein Sweilam, Sachin Puri, Rathod Bhagyashri Ramesh, Uppuluri Varuna Naga Venkata Arjun, Thukani Sathanantham Shanmugarajan, Nagaveni Pommala, Akiladevi Durairaj, Susithra Ethiraj, Nagarajan Shenbakadurai, Irfan Ahmad, Talha Bin Emran

First published: 24 March 2025

<https://doi.org/10.1002/cbdv.202500170>

 [VIEW METRICS](#)

Funding: The authors received no specific funding for this work.



 **Get access to the full version of this article. View access options below.**

Institutional Login



Access through your institution

Log in to Wiley Online Library

If you have previously obtained access with your personal account, please log in.

Log in with CONNECT

One account for all your research.

Wiley Online Library is part of the CONNECT Network.

Purchase Instant Access

48-Hour online access

\$12.00

[Details](#)



Online-only access

\$20.00

[Details](#)



PDF download and online access

\$49.00

[Details](#)



Check out

ABSTRACT

Neurodegenerative diseases (NDs) exhibit significant global public health challenges due to the lack of effective treatments. Berberine (BBR), a natural alkaloid compound in various plants, has been recognized for its potential neuroprotective properties. This review explores the current understanding of BBR's mechanisms of action and its therapeutic potential in preventing and treating NDs such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. BBR's neuroprotective properties are attributed to its multifaceted actions, including anti-inflammatory, antioxidant, antiapoptotic, and neurotrophic effects. In addition, BBR can influence many signaling pathways involved in neurodegeneration, including AMP-activated protein kinase (AMPK), nuclear factor erythroid 2-related factor 2, and brain-derived neurotrophic factor pathways. Furthermore, BBR targets vital signaling pathways, including AMPK, PI3K/Akt, and MAPK, which are essential for developing NDs. In addition, BBR's efficacy in reducing neurodegenerative pathology and improving cognitive function has been demonstrated through preclinical studies using cellular and animal models. Clinical trials demonstrating BBR's therapeutic potential in NDs have yielded promising results, but further research is needed to confirm its safety and efficacy in humans.

The authors declare no conflicts of interest. ▼

Data Availability Statement

The authors have nothing to report.

References

1 D. Fan, L. Liu, Z. Wu, and M. Cao, "Combating Neurodegenerative Diseases With the Plant Alkaloid Berberine: Molecular Mechanisms and Therapeutic Potential," *Current Neuropharmacology* **17** (2019): 563–579.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

2 D. G. Gadhawe, V. V. Sugandhi, S. K. Jha, et al., "Neurodegenerative Disorders: Mechanisms of Degeneration and Therapeutic Approaches With Their Clinical Relevance," *Ageing Research Reviews* **99** (2024): 102357.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

3 C. J. Stam, "Modern Network Science of Neurological Disorders," *Nature Reviews Neuroscience* **15** (2014): 683–695.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

4 V. L. Feigin, E. Nichols, T. Alam, et al., "Global, Regional, and National Burden of Neurological Disorders, 1990–2016: A Systematic Analysis for the Global Burden of Disease Study 2016," *Lancet Neurology* **18** (2019): 459–480.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

5 V. L. Feigin and T. Vos, "Global Burden of Neurological Disorders: From Global Burden of Disease Estimates to Actions," *Neuroepidemiology* **52** (2019): 1–2.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

6 H. Onohuean, A. O. Akiyode, O. Akiyode, S. I. Igbinoba, and A. I. Alagbonsi, "Epidemiology of Neurodegenerative Diseases in the East African Region: A Meta-Analysis," *Frontiers in Neurology*

7 R. Armstrong, "What Causes Neurodegenerative Disease?," *Folia Neuropathologica* **58** (2020): 93–112.

[PubMed](#) | [Web of Science](#) | [Google Scholar](#)

8 D. Chen, T. Zhang, and T. H. Lee, "Cellular Mechanisms of Melatonin: Insight From Neurodegenerative Diseases," *Biomolecules* **10** (2020): 1158.

[PubMed](#) | [Web of Science](#) | [Google Scholar](#)

9 A. Lekoubou, J. B. Echouffo-Tcheugui, and A. P. Kengne, "Epidemiology of Neurodegenerative Diseases in Sub-Saharan Africa: A Systematic Review," *BMC Public Health* **14** (2014): 653.

[PubMed](#) | [Web of Science](#) | [Google Scholar](#)

10 K. Gammon, "Neurodegenerative Disease: Brain Windfall," *Nature* **515** (2014): 299–300.

[PubMed](#) | [Google Scholar](#)

11 I. Y. Iskusnykh, A. A. Zakharova, E. D. Kryl'skii, and T. N. Popova, "Aging, Neurodegenerative Disorders, and Cerebellum," *International Journal of Molecular Sciences* **25** (2024): 1018.

[CAS](#) | [PubMed](#) | [Web of Science](#) | [Google Scholar](#)

12 J. Cohen, A. Mathew, K. D. Dourvetakis, et al., "Recent Research Trends in Neuroinflammatory and Neurodegenerative Disorders," *Cells* **13** (2024): 511.

[CAS](#) | [PubMed](#) | [Web of Science](#) | [Google Scholar](#)

13 T. Ahmed, M. Abdollahi, M. Daglia, S. F. Nabavi, and S. M. Nabavi, "Berberine and Neurodegeneration: A Review of Literature," *Pharmacological Reports* **67** (2015): 970–979.

[CAS](#) | [PubMed](#) | [Web of Science](#) | [Google Scholar](#)

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

15 Z. Cheng, C. Kang, S. Che, et al., "Berberine: A Promising Treatment for Neurodegenerative Diseases," *Frontiers in Pharmacology* 13 (2022): 845591.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

16 M. Akbar, A. Shabbir, K. Rehman, M. S. H. Akash, and M. A. Shah, "Neuroprotective Potential of Berberine in Modulating Alzheimer's Disease via Multiple Signaling Pathways," *Journal of Food Biochemistry* 45 (2021): e13936.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

17 M. Imenshahidi and H. Hosseinzadeh, "Berberine Neuroprotection and Antioxidant Activity," in *Oxidative Stress and Dietary Antioxidants in Neurological Diseases*, ed. C. R. Martin and V. R. Preedy (Academic Press, 2020), 199–216.

[Google Scholar](#)

18 E. Tian, G. Sharma, and C. Dai, "Neuroprotective Properties of Berberine: Molecular Mechanisms and Clinical Implications," *Antioxidants* 12 (2023): 1883.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

19 Z. Cai, C. Wang, and W. Yang, "Role of Berberine in Alzheimer's Disease," *Neuropsychiatric Disease and Treatment* 12 (2016): 2509–2520.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

20 S. Qin, H. Tang, W. Li, et al., "AMPK and Its Activator Berberine in the Treatment of Neurodegenerative Diseases," *Current Pharmaceutical Design* 26 (2020): 5054–5066.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

21 R. Mohi-Ud-Din, R. H. Mir, T. U. Wani, A. J. Shah, N. Banday, and F. H. Pottoo, "Berberine in the Treatment of Neurodegenerative Diseases and Nanotechnology Enabled Targeted

22 A. Mangoni, M. Grassi, L. Frattola, et al., "Effects of a MAO-B Inhibitor in the Treatment of Alzheimer Disease," *European Neurology* 31 (1991): 100–107.

23 J. Rabey, I. Sagi, M. Huberman, et al., "Rasagiline Mesylate, a New Mao-B Inhibitor for the Treatment of Parkinson's Disease: A Double-Blind Study as Adjunctive Therapy to Levodopa," *Clinical Neuropharmacology* 23 (2000): 324–330.

24 C. Caspersen, N. Wang, J. Yao, et al., "Mitochondrial A β : A Potential Focal Point for Neuronal Metabolic Dysfunction in Alzheimer's Disease," *FASEB Journal* 19 (2005): 2040–2041.

25 P. Poprac, K. Jomova, M. Simunkova, V. Kollar, C. J. Rhodes, and M. Valko, "Targeting Free Radicals in Oxidative Stress-Related Human Diseases," *Trends in Pharmacological Sciences* 38 (2017): 592–607.

26 Z. Li, T. Jiang, Q. Lu, et al., "Berberine Attenuated the Cytotoxicity Induced by T-BHP via Inhibiting Oxidative Stress and Mitochondria Dysfunction in PC-12 Cells," *Cellular and Molecular Neurobiology* 40 (2020): 587–602.

27 H. R. Sadeghnia, M. Kolangikhah, E. Asadpour, F. Forouzanfar, and H. Hosseinzadeh, "Berberine Protects Against Glutamate-Induced Oxidative Stress and Apoptosis in PC12 and N2a Cells," *Iranian Journal of Basic Medical Sciences* 20 (2017): 594–603.

28 D.-H. Lee, R. Gold, and R. A. Linker, "Mechanisms of Oxidative Damage in Multiple Sclerosis and Neurodegenerative Diseases: Therapeutic Modulation via Fumaric Acid Esters," *International*

29 J. S. de Oliveira, F. H. Abdalla, G. L. Dornelles, et al., "Neuroprotective Effects of berberine on Recognition Memory Impairment, Oxidative Stress, and Damage to the Purinergic System in Rats Submitted to Intracerebroventricular Injection of Streptozotocin," *Psychopharmacology* **236** (2019): 641–655.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

30 J.-H. Chen, S.-M. Huang, T.-W. Tan, et al., "Berberine Induces Heme Oxygenase-1 Up-Regulation Through Phosphatidylinositol 3-Kinase/AKT and NF-E2-Related Factor-2 Signaling Pathway in Astrocytes," *International Immunopharmacology* **12** (2012): 94–100.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

31 J. Bae, D. Lee, Y. K. Kim, M. Gil, J.-Y. Lee, and K. J. Lee, "Berberine Protects 6-Hydroxydopamine-Induced Human Dopaminergic Neuronal Cell Death Through the Induction of Heme Oxygenase-1," *Molecules and Cells* **35** (2013): 151–157.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

32 M. Chen, L. Li, C. Liu, and L. Song, "Berberine Attenuates A β -Induced Neuronal Damage Through Regulating miR-188/NOS1 in Alzheimer's Disease," *Molecular and Cellular Biochemistry* **474** (2020): 285–294.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

33 M. Ye, S. Fu, R. Pi, and F. He, "Neuropharmacological and Pharmacokinetic Properties of berberine: A Review of Recent Research," *Journal of Pharmacy and Pharmacology* **61** (2009): 831–837.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

34 C.-C. Zhang, F. Lu, J.-Q. Liang, and Y.-F. Zhou, "[Research Progress of Histone Deacetylase 6 Inhibitors in the Therapy of Ischemic Stroke]," *Sheng Li Xue Bao:[Acta Physiologica Sinica]* **70** (2018): 301.

[PubMed](#) | [Google Scholar](#)

Involved," *Brain Research* 1557 (2014): 26–33.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

36 M. Kim, K.-H. Cho, M.-S. Shin, et al., "Berberine Prevents Nigrostriatal Dopaminergic Neuronal Loss and Suppresses Hippocampal Apoptosis in Mice With Parkinson's disease," *International Journal of Molecular Medicine* 33 (2014): 870–878.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

37 M. Huang, X. Jiang, Y. Liang, Q. Liu, S. Chen, and Y. Guo, "Berberine Improves Cognitive Impairment by Promoting Autophagic Clearance and Inhibiting Production of β -Amyloid in APP/Tau/PS1 Mouse Model of Alzheimer's Disease," *Experimental Gerontology* 91 (2017): 25–33.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

38 H. N. Zhang, Y. J. Sun, H. Q. He, et al., "Berberine Promotes Nerve Regeneration Through IGFR-Mediated JNK-AKT Signal Pathway," *Molecular Medicine Reports* 18 (2018): 5030.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

39 A. Campisi, R. Acquaviva, S. Mastrojeni, et al., "Effect of Berberine and *Berberis aetnensis* C. Presl. Alkaloid Extract on Glutamate-Evoked Tissue Transglutaminase Up-Regulation in Astroglial Cell Cultures," *Phytotherapy Research* 25 (2011): 816–820.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

40 Y. Liang, C. Ye, Y. Chen, Y. Chen, S. Diao, and M. Huang, "Berberine Improves Behavioral and Cognitive Deficits in a Mouse Model of Alzheimer's Disease via Regulation of β -Amyloid Production and Endoplasmic Reticulum Stress," *ACS Chemical Neuroscience* 12 (2021): 1894–1904.

[CAS](#) | [PubMed](#) | [Google Scholar](#)

41 L. Lin, C. Li, D. Zhang, M. Yuan, C.-h. Chen, and M. Li, "Synergic Effects of Berberine and Curcumin on Improving Cognitive Function in an Alzheimer's Disease Mouse Model," *Neurochemical Research* 45 (2020): 1130–1141.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

Utilizing Drug Repurposing Strategy,” *Current Reviews in Clinical and Experimental Pharmacology* **18** (2023): 182–190.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

43 C. Zhang, C. Li, S. Chen, et al., “Berberine Protects Against 6-OHDA-Induced Neurotoxicity in PC12 Cells and Zebrafish Through Hormetic Mechanisms Involving PI3K/AKT/Bcl-2 and Nrf2/HO-1 Pathways,” *Redox Biology* **11** (2017): 1–11.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

44 J.-R. Zhu, H.-D. Lu, C. Guo, et al., “Berberine Attenuates Ischemia–Reperfusion Injury Through Inhibiting HMGB1 Release and NF-κB Nuclear Translocation,” *Acta Pharmacologica Sinica* **39** (2018): 1706–1715.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

45 F. Zhu and C. Qian, “Berberine Chloride Can Ameliorate the Spatial Memory Impairment and Increase the Expression of Interleukin-1beta and Inducible Nitric Oxide Synthase in the Rat Model of Alzheimer's Disease,” *BMC Neuroscience* **7** (2006).

[PubMed](#) | [Google Scholar](#)

46 H. M. Hussien, A. Abd-Elmegied, D. A. Ghareeb, H. S. Hafez, H. E. Ahmed, and N. A. El-Moneam, “Neuroprotective Effect of Berberine Against Environmental Heavy Metals-Induced Neurotoxicity and Alzheimer's-Like Disease in Rats,” *Food and Chemical Toxicology* **111** (2018): 432–444.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

47 D. Y. Lu, C. H. Tang, Y. H. Chen, and I. H. Wei, “Berberine Suppresses Neuroinflammatory Responses Through AMP-Activated Protein Kinase Activation in BV-2 Microglia,” *Journal of Cellular Biochemistry* **110** (2010): 697–705.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

48 S. Sadraie, Z. Kiasalari, M. Razavian, et al., “Berberine Ameliorates Lipopolysaccharide-Induced Learning and Memory Deficit in the Rat: Insights Into Underlying Molecular Mechanisms,” *Metabolic Brain Disease* **34** (2019): 245–255.

49 H. Deng and Z. Ma, "Protective Effects of Berberine Against MPTP-Induced Dopaminergic Neuron Injury Through Promoting Autophagy in Mice," *Food & Function* **12** (2021): 8366.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

50 J. Luo, R. Chen, S. Zeng, et al., "The Effects of Berberine on a Murine Model of Multiple Sclerosis and the SPHK1/S1P Signaling Pathway," *Biochemical and Biophysical Research Communications* **490** (2017): 927–932.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

51 T. M. Do, W. Alata, A. Dodacki, et al., "Altered Cerebral Vascular Volumes and Solute Transport at the Blood–Brain Barriers of Two Transgenic Mouse Models of Alzheimer's Disease," *Neuropharmacology* **81** (2014): 311–317.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

52 M. M. Matuszyk, C. J. Garwood, L. Ferraiuolo, J. E. Simpson, R. A. Staniforth, and S. B. Wharton, "Biological and Methodological Complexities of Beta-Amyloid Peptide: Implications for Alzheimer's Disease Research," *Journal of Neurochemistry* **160** (2022): 434–453.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

53 C. Ye, Y. Liang, Y. Chen, et al., "Berberine Improves Cognitive Impairment by Simultaneously Impacting Cerebral Blood Flow and β -Amyloid Accumulation in an APP/Tau/PS1 Mouse Model of Alzheimer's Disease," *Cells* **10** (2021): 1161.

[CAS](#) | [PubMed](#) | [Google Scholar](#)

54 H. K. Moghaddam, T. Baluchnejadmojarad, M. Roghani, et al., "Berberine Ameliorate Oxidative Stress and Astroglialosis in the Hippocampus of STZ-Induced Diabetic Rats," *Molecular Neurobiology* **49** (2014): 820–826.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

55 G. Ibrahim Fouad and K. A. Ahmed, "Neuroprotective Potential of Berberine Against Doxorubicin-Induced Toxicity in Rat's Brain," *Neurochemical Research* **46** (2021): 3247–3263.

56 Y. Chen, Y. Chen, Y. Liang, H. Chen, X. Ji, and M. Huang, "Berberine Mitigates Cognitive Decline in an Alzheimer's Disease Mouse Model by Targeting Both Tau Hyperphosphorylation and Autophagic Clearance," *Biomedicine & Pharmacotherapy* 121 (2020): 109670.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

57 S. S. K. Durairajan, L.-F. Liu, J.-H. Lu, et al., "Berberine Ameliorates β -Amyloid Pathology, Gliosis, and Cognitive Impairment in an Alzheimer's Disease Transgenic Mouse Model," *Neurobiology of Aging* 33 (2012): 2903–2919.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

58 S. R. Saleh, M. M. Abady, M. Nofal, et al., "Berberine Nanoencapsulation Attenuates Hallmarks of Scoplamine Induced Alzheimer's-Like Disease in Rats," *Current Reviews in Clinical and Experimental Pharmacology* 16 (2021): 139.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

59 W.-T. Xuan, H. Wang, P. Zhou, et al., "Berberine Ameliorates Rats Model of Combined Alzheimer's Disease and Type 2 Diabetes Mellitus via the Suppression of Endoplasmic Reticulum Stress," *3 Biotech* 10 (2020): 359.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

60 J. S. de Oliveira, F. H. Abdalla, G. L. Dornelles, et al., "Berberine Protects Against Memory Impairment and Anxiogenic-Like Behavior in Rats Submitted to Sporadic Alzheimer's-Like Dementia: Involvement of Acetylcholinesterase and Cell Death," *Neurotoxicology* 57 (2016): 241–250.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

61 A. E. Abd El-Wahab, D. A. Ghareeb, E. E. Sarhan, M. M. Abu-Serie, and M. A. El Demellawy, "In Vitro Biological Assessment of *Berberis vulgaris* and Its Active Constituent, Berberine: Antioxidants, Anti-Acetylcholinesterase, Anti-Diabetic and Anticancer Effects," *BMC Complementary and Alternative Medicine* 13 (2013): 218.

[PubMed](#) | [Google Scholar](#)

[PubMed](#) | [Google Scholar](#)

63 H. Ismail, D. Khalid, D. Waseem, et al., "Bioassays Guided Isolation of Berberine From *Berberis lycium* and Its Neuroprotective Role in Aluminium Chloride Induced Rat Model of Alzheimer's Disease Combined With In Silico Molecular Docking," *PLoS One* **18** (2023): e0286349.

[CAS](#) | [PubMed](#) | [Google Scholar](#)

64 S. Huang, H. Liu, Y. Lin, et al., "Berberine Protects Against NLRP3 Inflammasome via Ameliorating Autophagic Impairment in MPTP-Induced Parkinson's Disease Model," *Frontiers in Pharmacology* **11** (2021): 618787.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

65 I. H. Kwon, H. S. Choi, K. S. Shin, et al., "Effects of Berberine on 6-Hydroxydopamine-Induced Neurotoxicity in PC12 Cells and a Rat Model of Parkinson's Disease," *Neuroscience Letters* **486** (2010): 29–33.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

66 K. S. Shin, H. S. Choi, T. T. Zhao, et al., "Neurotoxic Effects of Berberine on Long-Term L-DOPA Administration in 6-Hydroxydopamine-Lesioned Rat Model of Parkinson's Disease," *Archives of Pharmacal Research* **36** (2013): 759–767.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

67 M. J. Tavaf, A. Soltanmohammadi, S. Zargarani, et al., "Berberine Promotes Immunological Outcomes and Decreases Neuroinflammation in the Experimental Model of Multiple Sclerosis Through the Expansion of Treg and Th2 Cells," *Immunity, Inflammation and Disease* **11** (2023): e766.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

68 X. Qin, B. T. Guo, B. Wan, et al., "Regulation of Th1 and Th17 Cell Differentiation and Amelioration of Experimental Autoimmune Encephalomyelitis by Natural Product Compound Berberine," *Journal of Immunology* **185** (2010): 1855–1863.

69 Y. Jiang, A. Wu, C. Zhu, et al., "The Protective Effect of Berberine Against Neuronal Damage by Inhibiting Matrix Metalloproteinase-9 and Laminin Degradation in Experimental Autoimmune Encephalomyelitis," *Neurological Research* 35 (2013): 360–368.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

70 W. Jiang, W. Wei, M. A. Gaertig, S. Li, and X.-J. Li, "Therapeutic Effect of Berberine on Huntington's Disease Transgenic Mouse Model," *PLoS One* 10 (2015): e0134142.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

71 S. G. Ravandi, M. Shabani, H. Bashiri, M. S. Goraghani, M. Khodamoradi, and M. Nozari, "Ameliorating Effects of Berberine on MK-801-Induced Cognitive and Motor Impairments in a Neonatal Rat Model of Schizophrenia," *Neuroscience Letters* 706 (2019): 151–157.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

72 N. Gholizadeh, A. Dalimi, F. Ghaffarifar, et al., "Berberine Improves Inhibitory Avoidance Memory Impairment of *Toxoplasma gondii*-Infected Rat Model of Ketamine-Induced Schizophrenia," *BMC Complementary Medicine and Therapies* 23 (2023): 303.

[CAS](#) | [PubMed](#) | [Google Scholar](#)

73 M. Li, Y. Liu, Y. Qiu, et al., "The Effect of Berberine Adjunctive Treatment on Glycolipid Metabolism in Patients With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial," *Psychiatry Research* 300 (2021): 113899.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

74 M. Li, Y. Qiu, J. Zhang, et al., "Improvement of Adjunctive Berberine Treatment on Negative Symptoms in Patients With Schizophrenia," *European Archives of Psychiatry and Clinical Neuroscience* 272 (2022): 633–642.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

75 E. M. Sarani, F. Ghorbannezhad, M. H. Meshkibaf, M. Shakibae, and S. H. Mosavat, "Evaluation of the Effect of Alkaloid Berberine on the Positive and Negative Symptoms of the

[Google Scholar](#) 

76 M. Chan, Z. Qin, S. C. Man, et al., "Adjunctive Berberine Reduces Antipsychotic-Associated Weight Gain and Metabolic Syndrome in Patients With Schizophrenia: A Randomized Controlled Trial," *Psychiatry and Clinical Neurosciences* 76 (2022): 77–85.

[CAS](#)  | [PubMed](#)  | [Web of Science®](#)  | [Google Scholar](#) 

77 Y. Li, X. Zhao, X. Feng, X. Liu, C. Deng, and C.-H. Hu, "Berberine Alleviates Olanzapine-Induced Adipogenesis via the AMPK α –SREBP Pathway in 3T3-L1 Cells," *International Journal of Molecular Sciences* 17 (2016): 1865.

[PubMed](#)  | [Google Scholar](#) 

78 M. L. Aski, M. E. Rezvani, M. Khaksari, et al., "Neuroprotective Effect of Berberine Chloride on Cognitive Impairment and Hippocampal Damage in Experimental Model of Vascular Dementia," *Iranian Journal of Basic Medical Sciences* 21 (2018): 53.

[PubMed](#)  | [Web of Science®](#)  | [Google Scholar](#) 

79 S. Yin, W. Bai, P. Li, et al., "Berberine Suppresses the Ectopic Expression of miR-133a in Endothelial Cells to Improve Vascular Dementia in Diabetic Rats," *Clinical and Experimental Hypertension* 41 (2019): 708–716.

[CAS](#)  | [PubMed](#)  | [Web of Science®](#)  | [Google Scholar](#) 

80 D. P. Singh and K. Chopra, "Verapamil Augments the Neuroprotectant Action of Berberine in Rat Model of Transient Global Cerebral Ischemia," *European Journal of Pharmacology* 720 (2013): 98–106.

[CAS](#)  | [PubMed](#)  | [Web of Science®](#)  | [Google Scholar](#) 

81 K. Sun, Z.-L. Luo, C. Hu, T.-L. Gong, G.-H. Tang, and S.-P. Wu, "[Protective Effect and Immune Mechanism of Berberine on Cerebral Ischemia/Reperfusion Injury in Rats]," *Chinese Journal of Applied Physiology* 36 (2020): 656.

[Google Scholar](#) 

87 (2018): 54–59.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

83 D. Mehboodi, A. Shahedi, M. Namavar, M. Yadegari, and F. Mazaheri, "Berberine Alleviates Cerebellar Damage in Global Cerebral Ischemia: A Comprehensive Study With Stereological Analysis, Evaluation of the Antioxidant Response, and Locomotor Function in rat Models," *Traditional & Kampo Medicine* 11, no. 3 (2024): 222–229.

[CAS](#) | [Web of Science®](#) | [Google Scholar](#)

84 C.-C. Chen, T.-H. Hung, C. Y. Lee, et al., "Berberine Protects Against Neuronal Damage via Suppression of Glia-Mediated Inflammation in Traumatic Brain Injury," *PLoS One* 9 (2014): e115694.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

85 S.-X. Huang, G. Qiu, F.-R. Cheng, et al., "Berberine Protects Secondary Injury in Mice With Traumatic Brain Injury through Anti-Oxidative and Anti-Inflammatory Modulation," *Neurochemical Research* 43 (2018): 1814–1825.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

86 J. Wang and Y. Zhang, "Neuroprotective Effect of Berberine Agonist Against Impairment of Learning and Memory Skills in Severe Traumatic Brain Injury via Sirt1/p38 MAPK Expression," *Molecular Medicine Reports* 17 (2018): 6881.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

87 P. M. Tentu, M. R. Bazaz, T. Pasam, et al., "Oxyberberine an Oxoderivative of Berberine Confers Neuroprotective Effects in Controlled-Cortical Impact Mouse Model of Traumatic Brain Injury," *International Journal of Neuroscience* 135 (2023): 80–95.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

88 X. Wu, X. Liu, L. Yang, and Y. Wang, "Berberine Protects Against Neurological Impairments and Blood-Brain Barrier Injury in Mouse Model of Intracerebral Hemorrhage," *Neuroimmunomodulation* 29 (2022): 317–326.

89 S. Anbai, F. Niazi, A. Siahposht-Khachaki, L. Sefidari, and D. Farzin, "Neuroprotective Effects of Berberine After Severe Traumatic Brain Injury in Male Rats: The Role of IL-1 β and IL 10," *Journal of Mazandaran University of Medical Sciences* 31 (2022): 1–13.

[Google Scholar](#) 

90 J. Wang, M. Zhang, H. Li, et al., "Berberine Improves Motor Function Recovery by Inhibiting Endoplasmic Reticulum Stress-Induced Neuronal Apoptosis via AMPK Activation in Rats With Spinal Cord Injury," *International Journal of Clinical and Experimental Pathology* 10 (2017): 4900.

[CAS](#)  | [Web of Science®](#)  | [Google Scholar](#) 

91 Y. Suzuki, S. Nakagawa, T. Endo, et al., "High-Throughput Screening Assay Identifies Berberine and Mubritinib as Neuroprotection Drugs for Spinal Cord Injury via Blood-Spinal Cord Barrier Protection," *Neurotherapeutics* 19 (2022): 1976–1991.

[CAS](#)  | [PubMed](#)  | [Web of Science®](#)  | [Google Scholar](#) 

92 H. Duan, X. Yang, C. Hao, W. Xue, and X. Qiao, "Effects of Berberine on Neurological Recovery After Spinal Cord Injury in Rats," *FASEB Journal* 36 (2022).

[Web of Science®](#)  | [Google Scholar](#) 

93 H. Wang, C. Liu, X. Mei, et al., "Berberine Attenuated Pro-Inflammatory Factors and Protect Against Neuronal Damage via Triggering Oligodendrocyte Autophagy in Spinal Cord Injury," *Oncotarget* 8 (2017): 98312–98321.

[PubMed](#)  | [Web of Science®](#)  | [Google Scholar](#) 

94 Z.-Y. Cai, C.-L. Wang, T.-T. Lu, and W.-M. Yang, "Berberine Alleviates Amyloid-Beta Pathogenesis via Activating LKB1/AMPK Signaling in the Brain of APP/PS1 Transgenic Mice," *Current Molecular Medicine* 19 (2019): 342–348.

[CAS](#)  | [PubMed](#)  | [Web of Science®](#)  | [Google Scholar](#) 

95 H. J. Kim, "Berberine Ameliorates Allodynia Induced by Chronic Constriction Injury of the Sciatic Nerve in Rats," *Journal of Medicinal Food* 18 (2015): 909–915.

96 S. O. Kim and H. J. Kim, "Berberine Ameliorates Cold and Mechanical Allodynia in a Rat Model of Diabetic Neuropathy," *Journal of Medicinal Food* **16** (2013): 511–517.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

97 X.-H. Zhang, L. Peng, J. Zhang, et al., "Berberine Ameliorates Subarachnoid Hemorrhage Injury via Induction of Sirtuin 1 and Inhibiting HMGB1/NF- κ B Pathway," *Frontiers in Pharmacology* **11** (2020): 1073.

[CAS](#) | [PubMed](#) | [Google Scholar](#)

98 J. E. Novak, B. W. Agranoff, and S. K. Fisher, "Increased Expression of G α Q/11 and of Phospholipase-C β 1/4 in Differentiated Human NT2-N Neurons," *Journal of Neurochemistry* **74** (2000): 2322–2330.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

99 Y.-Y. Hsu, Y.-T. Tseng, and Y.-C. Lo, "Berberine, a Natural Antidiabetes Drug, Attenuates Glucose Neurotoxicity and Promotes Nrf2-related Neurite Outgrowth," *Toxicology and Applied Pharmacology* **272** (2013): 787–796.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

100 C. Halbsguth, O. Meissner, and H. Häberlein, "Positive Cooperation of Protoberberine Type 2 Alkaloids From *Corydalis cava* on the GABA A Binding Site," *Planta Medica* **69** (2003): 305–309.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

101 T. Lee, H. Heo, and Y. K. Kwon, "Effect of Berberine on Cell Survival in the Developing Rat Brain Damaged by MK-801," *Experimental Neurobiology* **19** (2010): 140–145.

[PubMed](#) | [Google Scholar](#)

102 J. Wu and G. Z. Jin, "Tetrahydroberberine Blocks Membrane K⁺ Channels Underlying Its Inhibition of Intracellular Message-Mediated Outward Currents in Acutely Dissociated CA1 Neurons From Rat Hippocampus," *Brain Research* **775** (1997): 214–218.

103 F. Lacaille, C. Everaerts, and J.-F. Ferveur, "Feminization and Alteration of *Drosophila* Taste Neurons Induce Reciprocal Effects on Male Avoidance Behavior," *Behavior Genetics* 39 (2009): 554–563.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

104 M. Goedert and M. G. Spillantini, "A Century of Alzheimer's Disease," *Science* 314 (2006): 777–781.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

105 F. M. Ribeiro, L. B. Vieira, R. G. Pires, R. P. Olmo, and S. S. Ferguson, "Metabotropic Glutamate Receptors and Neurodegenerative Diseases," *Pharmacological Research* 115 (2017): 179–191.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

106 N. Shinjyo and K. Kita, "Infection and Immunometabolism in the Central Nervous System: A Possible Mechanistic Link Between Metabolic Imbalance and Dementia," *Frontiers in Cellular Neuroscience* 15 (2021): 765217.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

107 D. Ameen and B. Michniak-Kohn, "Transdermal Delivery of Dimethyl Fumarate for Alzheimer's Disease: Effect of Penetration Enhancers," *International Journal of Pharmaceutics* 529 (2017): 465–473.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

108 A. Bandiwadekar, J. Jose, M. Khayatkashani, S. Habtemariam, H. R. Khayat Kashani, and S. M. Nabavi, "Emerging Novel Approaches for the Enhanced Delivery of Natural Products for the Management of Neurodegenerative Diseases," *Journal of Molecular Neuroscience* 72 (2022): 653–676.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

109 J. Fan, B. Li, T. Ge, et al., "Berberine Produces Antidepressant-Like Effects in Ovariectomized Mice," *Scientific Reports* 7 (2017): 1310.

110 N. Zhang, Y. Gao, S. Yu, X. Sun, and K. Shen, "Berberine Attenuates A β 42-Induced Neuronal Damage Through Regulating circHDAC9/miR-142-5p Axis in Human Neuronal Cells," *Life Sciences* **252** (2020): 117637.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

111 M. Asai, N. Iwata, A. Yoshikawa, et al., "Berberine Alters the Processing of Alzheimer's Amyloid Precursor Protein to Decrease A β Secretion," *Biochemical and Biophysical Research Communications* **352** (2007): 498–502.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

112 M. Raju, S. S. Kunde, S. T. Auti, Y. A. Kulkarni, and S. Wairkar, "Berberine Loaded Nanostructured Lipid Carrier for Alzheimer's Disease: Design, Statistical Optimization and Enhanced In Vivo Performance," *Life Sciences* **285** (2021): 119990.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

113 B. R. Bloem, M. S. Okun, and C. Klein, "Parkinson's Disease," *Lancet* **397** (2021): 2284–2303.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

114 L. V. Kalia and A. E. Lang, "Parkinson's Disease," *Lancet* **386** (2015): 896–912.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

115 J. Aguado and E. J. Wolvetang, "Exploring Aging Interventions in Human Brain Organoids," *Aging* **14** (2022): 1592–1593.

[PubMed](#) | [Google Scholar](#)

116 C.-W. Xiao, Q.-A. Ji, Q. Wei, Y. Liu, L.-J. Pan, and G.-L. Bao, "Digital Gene Expression Analysis of *Microsporium canis* Exposed to Berberine Chloride," *PLoS One* **10** (2015): e0124265.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

Convenient for Bioimaging Experiments,” *Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology* **249** (2021): 109151.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

118 Y. Wang, Q. Tong, S.-R. Ma, et al., “Oral Berberine Improves Brain Dopa/Dopamine Levels to Ameliorate Parkinson's Disease by Regulating Gut Microbiota,” *Signal Transduction and Targeted Therapy* **6** (2021): 77.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

119 J. Li, P. Meng, J. Zhang, and M. He, “Effect of Berberine Hydrochloride on the Diversity of Intestinal Flora in Parkinson's Disease Patients,” *Contrast Media & Molecular Imaging* **2022** (2022): 8381870.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

120 V. Kahale, A. Mhaskar, P. Shelat, R. Pooja, N. Gaikwad, and D. Mundhada, “To Determine the Effect of Berberine on 6-OHDA Induced Memory Impairment in Parkinson's Disease in Rodents,” *Pharma Innovation* **3** (2014): 101.

[CAS](#) | [Google Scholar](#)

121 W. Jing, Y.-Q. Zhang, L. Dong-Qing, Y. Xu-Tao, H. Jiang, and Y.-B. Zhang, “Demethylenetetrahydroberberine Protects Dopaminergic Neurons in a Mouse Model of Parkinson's Disease,” *Chinese Journal of Natural Medicines* **20** (2022): 111–119.

[PubMed](#) | [Google Scholar](#)

122 R. Dobson and G. Giovannoni, “Multiple Sclerosis—A Review,” *European Journal of Neurology* **26** (2019): 27–40.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

123 S. Kulkarni and A. Dhir, “Berberine: A Plant Alkaloid With Therapeutic Potential for central Nervous System Disorders,” *Phytotherapy Research* **24** (2010): 317–324.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

125 X. Ma, Y. Jiang, A. Wu, et al., "Berberine Attenuates Experimental Autoimmune Encephalomyelitis in C57 BL/6 Mice," *PLoS One* 5 (2010): e13489.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

126 S. Patel, D. Sharma, K. Kalia, and V. Tiwari, "Crosstalk Between Endoplasmic Reticulum Stress and Oxidative Stress in Schizophrenia: The Dawn of New Therapeutic Approaches," *Neuroscience & Biobehavioral Reviews* 83 (2017): 589.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

127 T. Tarrago, N. Kichik, J. Seguí, and E. Giralt, "The Natural Product Berberine Is a Human Prolyl Oligopeptidase Inhibitor," *ChemMedChem* 2 (2007): 354–359.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

128 Z. Pu, H. Wen, H. Jiang, Q. Hou, and H. Yan, "Berberine Improves Negative Symptoms and Cognitive Function in Patients With Chronic Schizophrenia via Anti-Inflammatory Effect: A Randomized Clinical Trial," *Chinese Medicine* 18 (2023): 41.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

129 Y. Qiu, M. Li, Y. Zhang, et al., "Berberine Treatment for Weight Gain in Patients With Schizophrenia by Regulating Leptin Rather Than Adiponectin," *Asian Journal of Psychiatry* 67 (2022): 102896.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

130 M. Y. Chan, S. C. Man, M. Lam, et al., "Berberine for Antipsychotic-Induced Metabolic Syndrome in Patients With Schizophrenia Spectrum Disorders: Abridged Secondary Publication," *Hong Kong Medical Journal* 29, no. 3 Supplement 3 (2023): 1.

[Web of Science®](#) | [Google Scholar](#)

Schizophrenia,” *Journal of Hainan Medical University* 23 (2017): 151.

[Google Scholar](#) 

132 H. Zou, J. Long, Q. Zhang, et al., “Induced Cortical Neurogenesis After Focal Cerebral Ischemia—Three Active Components From Huang-Lian-Jie-Du Decoction,” *Journal of Ethnopharmacology* 178 (2016): 115–124.

[CAS](#)  | [PubMed](#)  | [Web of Science®](#)  | [Google Scholar](#) 

133 X.-Q. Zhou, X.-N. Zeng, H. Kong, and X.-L. Sun, “Neuroprotective Effects of Berberine on Stroke Models In Vitro and In Vivo,” *Neuroscience Letters* 447 (2008): 31–36.

[CAS](#)  | [PubMed](#)  | [Web of Science®](#)  | [Google Scholar](#) 

134 K.-Y. Yoo, I. K. Hwang, B. O. Lim, et al., “Berberry Extract Reduces Neuronal Damage and N-Methyl-D-Aspartate Receptor 1 Immunoreactivity in the Gerbil Hippocampus After Transient Forebrain Ischemia,” *Biological and Pharmaceutical Bulletin* 29 (2006): 623–628.

[CAS](#)  | [PubMed](#)  | [Web of Science®](#)  | [Google Scholar](#) 

135 F. Wang, G. Zhao, L. Cheng, H.-Y. Zhou, L.-Y. Fu, and W.-X. Yao, “Effects of Berberine on Potassium Currents in Acutely Isolated CA1 Pyramidal Neurons of Rat Hippocampus,” *Brain Research* 999 (2004): 91–97.

[CAS](#)  | [PubMed](#)  | [Web of Science®](#)  | [Google Scholar](#) 

136 J. S. Hong, Y. K. Chu, H. Lee, et al., “Effects of Berberine on Hippocampal Neuronal Damage and Matrix Metalloproteinase-9 Activity Following Transient Global Cerebral Ischemia,” *Journal of Neuroscience Research* 90 (2012): 489–497.

[CAS](#)  | [PubMed](#)  | [Web of Science®](#)  | [Google Scholar](#) 

137 L. Zhao, H. Li, Q. Gao, et al., “Berberine Attenuates Cerebral Ischemia-Reperfusion Injury Induced Neuronal Apoptosis by Down-Regulating the CNPY2 Signaling Pathway,” *Frontiers in Pharmacology* 12 (2021): 609693.

[CAS](#)  | [PubMed](#)  | [Web of Science®](#)  | [Google Scholar](#) 

Neurochemical Research **43** (2018): 702–710.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

139 D.-Q. Liu, S.-P. Chen, J. Sun, et al., “Berberine Protects Against Ischemia-Reperfusion Injury: A Review of Evidence From Animal Models and Clinical Studies,” *Pharmacological Research* **148** (2019): 104385.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

140 X. Zhang, X. Zhang, C. Wang, et al., “Neuroprotection of Early and Short-Time Applying Berberine in the Acute Phase of Cerebral Ischemia: Up-Regulated pAkt, pGSK and pCREB, Down-Regulated NF-κB Expression, Ameliorated BBB Permeability,” *Brain Research* **1459** (2012): 61–70.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

141 Y.-S. Chai, J. Hu, F. Lei, et al., “Effect of Berberine on Cell Cycle Arrest and Cell Survival During Cerebral Ischemia and Reperfusion and Correlations With p53/Cyclin D1 and PI3K/Akt,” *European Journal of Pharmacology* **708** (2013): 44–55.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

142 R. Azadi, S. E. Mousavi, N. M. Kazemi, H. Yousefi-Manesh, S. M. Rezayat, and M. R. Jaafari, “Anti-Inflammatory Efficacy of Berberine Nanomicelle for Improvement of Cerebral Ischemia: Formulation, Characterization and Evaluation in Bilateral Common Carotid Artery Occlusion Rat Model,” *BMC Pharmacology and Toxicology* **22** (2021): 54.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

143 N. Wang, Y. Tian, F. Yan, et al., “Berberine Protects Against Chronic Cerebral Hypoperfusion-Induced Cognitive Impairment and Hippocampal Damage via Regulation of the ERK/Nrf2 Pathway,” *Journal of Chemical Neuroanatomy* **123** (2022): 102119.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

144 X. Wang, J. Zhang, S. Wang, et al., “Berberine Modulates Gut Microbiota to Attenuate Cerebral Ferroptosis Induced by Ischemia-Reperfusion in Mice,” *European Journal of Pharmacology* **953** (2023): 175782.

145 T. S. Jensen and N. B. Finnerup, "Allodynia and Hyperalgesia in Neuropathic Pain: Clinical Manifestations and Mechanisms," *Lancet Neurology* 13 (2014): 924–935.

| [PubMed](#) | [Web of Science®](#) | [Google Scholar](#) |

146 H. Shuai, M. Hua, J. Tingting, et al., "Inhibitory Effect of Berberine on Morphine Tolerance and Hyperalgesia in Mice," *Journal of Traditional Chinese Medicine* 43 (2023): 915.

| [Google Scholar](#) |

147 M. Sandeep and C. Nandini, "Influence of Quercetin, Naringenin and Berberine on Glucose Transporters and Insulin Signalling Molecules in Brain of Streptozotocin-Induced Diabetic Rats," *Biomedicine & Pharmacotherapy* 94 (2017): 605.

| [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#) |

148 S. A. Adefegha, F. A. Dada, S. I. Oyeleye, and G. Oboh, "Effects of Berberine on Cholinesterases and Monoamine Oxidase Activities, and Antioxidant Status in the Brain of Streptozotocin (STZ)-induced Diabetic Rats," *Journal of Basic and Clinical Physiology and Pharmacology* 33 (2022): 389–397.

| [CAS](#) | [Google Scholar](#) |

149 N. Shinjyo, J. Parkinson, J. Bell, T. Katsuno, and A. Bligh, "Berberine for Prevention of Dementia Associated With Diabetes and Its Comorbidities: A Systematic Review," *Journal of Integrative Medicine* 18 (2020): 125–151.

| [PubMed](#) | [Web of Science®](#) | [Google Scholar](#) |

150 Y. Hao, J. Li, S. Yue, S. Wang, S. Hu, and B. Li, "Neuroprotective Effect and Possible Mechanisms of Berberine in Diabetes-Related Cognitive Impairment: A Systematic Review and Meta-Analysis of Animal Studies," *Frontiers in Pharmacology* 13 (2022): 917375.

| [CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#) |

151 S. Dewanjee, S. Das, A. K. Das, et al., "Molecular Mechanism of Diabetic Neuropathy and Its Pharmacotherapeutic Targets," *European Journal of Pharmacology* 833 (2018): 472–523.

152 V. G. Yerra, A. K. Kalvala, B. Sherkhane, A. Areti, and A. Kumar, "Adenosine Monophosphate-Activated Protein Kinase Modulation by Berberine Attenuates Mitochondrial Deficits and Redox Imbalance in Experimental Diabetic Neuropathy," *Neuropharmacology* **131** (2018): 256–270.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

153 J. Zhou, X. Du, M. Long, et al., "Neuroprotective Effect of Berberine Is Mediated by MAPK Signaling Pathway in Experimental Diabetic Neuropathy in Rats," *European Journal of Pharmacology* **774** (2016): 87–94.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

154 F. Gao, Y. Gao, Y.-F. Liu, L. Wang, and Y.-j. Li, "Berberine Exerts an Anticonvulsant Effect and Ameliorates Memory Impairment and Oxidative Stress in a Pilocarpine-Induced Epilepsy Model in the Rat," *Neuropsychiatric Disease and Treatment* **10** (2014): 2139.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

155 T. B. Mojarad and M. Roghani, "The Anticonvulsant and Antioxidant Effects of Berberine in Kainate-Induced Temporal Lobe Epilepsy in Rats," *Basic and Clinical Neuroscience* **5** (2014): 124.

[PubMed](#) | [Google Scholar](#)

156 H. R. Sadeghnia, A. R. Taji, F. Forouzanfar, and H. Hosseinzadeh, "Berberine Attenuates Convulsing Behavior and Extracellular Glutamate and Aspartate Changes in 4-Aminopyridine Treated Rats," *Iranian Journal of Basic Medical Sciences* **20** (2017): 588.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

157 H. B. Ghanem, M. N. Emam, A. D. A. Mohammed, and A.-E. R. Nagi, "Impact of Berberine on Some Epigenetic, Transcription Regulation and Inflammatory Biomarkers in a Mice Model of Epilepsy," *Reports of Biochemistry & Molecular Biology* **10** (2021): 362.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

158 A. E. El-Nahas, H. M. Elbedaiwy, I. M. Masoud, R. G. Aly, M. W. Helmy, and A. H. El-Kamel, "Berberine-Loaded Zein/Hyaluronic Acid Composite Nanoparticles for Efficient Brain Uptake to

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

159 H. Zhu, Z. Wu, Y. Yu, et al., "Integrated Non-Targeted Metabolomics and Network Pharmacology to Reveal the Mechanisms of Berberine in the Long-Term Treatment of PTZ-Induced Epilepsy," *Life Sciences* **336** (2024): 122347.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

160 Y.-Y. Hsu, C.-S. Chen, S.-N. Wu, Y.-J. Jong, and Y.-C. Lo, "Berberine Activates Nrf2 Nuclear Translocation and Protects Against Oxidative Damage via a Phosphatidylinositol 3-Kinase/Akt-Dependent Mechanism in NSC34 Motor Neuron-Like Cells," *European Journal of Pharmaceutical Sciences* **46** (2012): 415–425.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

161 J. Hu, Y. Chai, Y. Wang, et al., "PI3K p55 γ Promoter Activity Enhancement Is Involved in the Anti-Apoptotic Effect of Berberine Against Cerebral Ischemia–Reperfusion," *European Journal of Pharmacology* **674** (2012): 132–142.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

162 H.-S. Cui, K. Matsumoto, Y. Murakami, H. Hori, Q. Zhao, and R. Obi, "Berberine Exerts Neuroprotective Actions Against In Vitro Ischemia-Induced Neuronal Cell Damage in Organotypic Hippocampal Slice Cultures: Involvement of B-Cell Lymphoma 2 Phosphorylation Suppression," *Biological and Pharmaceutical Bulletin* **32** (2009): 79–85.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

163 F. Benaissa, H. Mohseni-Rad, P. Rahimi-Moghaddam, and M. Mahmoudian, "Berberine Reduces the Hypoxic-Ischemic Insult in Rat Pup Brain," *Acta Physiologica Hungarica* **96** (2009): 213–220.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

164 P. Bhutada, Y. Mundhada, K. Bansod, et al., "Protection of Cholinergic and Antioxidant System Contributes to the Effect of Berberine Ameliorating Memory Dysfunction in Rat Model of Streptozotocin-Induced Diabetes," *Behavioural Brain Research* **220** (2011): 30–41.

165 Y. L. Siow, L. Sarna, and O. Karmin, "Redox Regulation in Health and Disease—Therapeutic Potential of Berberine," *Food Research International* **44** (2011): 2409–2417.

[CAS](#) | [Web of Science®](#) | [Google Scholar](#)

166 A. Luo and Y. Fan, "Antioxidant Activities of Berberine Hydrochloride," *Journal of Medicinal Plants Research* **5** (2011): 3702.

[CAS](#) | [Web of Science®](#) | [Google Scholar](#)

167 M. Tilaoui, A. Jaafari, H. Ait Mouse, and A. Zyad, "Studies on the Dual Cytotoxicity and Antioxidant Properties of *Berberis vulgaris* Extracts and Its Main Constituent Berberine," *Advances in Pharmacological and Pharmaceutical Sciences* **2018** (2018): 3018498.

[Google Scholar](#)

168 Z. Xu, W. Feng, Q. Shen, et al., "Rhizoma Coptidis and Berberine as a Natural Drug to Combat Aging and Aging-Related Diseases via Anti-Oxidation and AMPK Activation," *Aging and Disease* **8** (2017): 760.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

169 X. Lin and N. Zhang, "Berberine: Pathways to Protect Neurons," *Phytotherapy Research* **32** (2018): 1501–1510.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

170 J. Fusi, S. Bianchi, S. Daniele, et al., "An In Vitro Comparative Study of the Antioxidant Activity and SIRT1 Modulation of Natural Compounds," *Biomedicine & Pharmacotherapy* **101** (2018): 805.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

171 A. Kumar, K. Chopra, M. Mukherjee, R. Pottabathini, and D. K. Dhull, "Current Knowledge and Pharmacological Profile of Berberine: An Update," *European Journal of Pharmacology* **761** (2015): 288–297.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

Journal of Basic Medical Sciences 20 (2017): 538.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

173 K. N. Nam, J. H. Kim, H. J. Jung, et al., "Berberine Inhibits Inflammatory Activation of Rat Brain Microglia," *Neural Regeneration Research* 5 (2010): 1384.

[CAS](#) | [Web of Science®](#) | [Google Scholar](#)

174 J. H. Kurth, M. C. Kurth, S. E. Poduslo, and J. D. Schwankhaus, "Association of a Monoamine Oxidase B Allele With Parkinson's Disease," *Annals of Neurology* 33 (1993): 368–372.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

175 A. C. Rego and C. R. Oliveira, "Mitochondrial Dysfunction and Reactive Oxygen Species in Excitotoxicity and Apoptosis: Implications for the Pathogenesis of Neurodegenerative Diseases," *Neurochemical Research* 28 (2003): 1563–1574.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

176 J. St-Pierre, S. Drori, M. Uldry, et al., "Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional Coactivators," *Cell* 127 (2006): 397–408.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

177 L. Yang, H.-Y. He, and X.-J. Zhang, "Increased Expression of Intranuclear AChE Involved in Apoptosis of SK-N-SH Cells," *Neuroscience Research* 42 (2002): 261–268.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

178 U. Holzgrabe, P. Kapková, V. Alptüzün, J. Scheiber, and E. Kugelmann, "Targeting Acetylcholinesterase to Treat Neurodegeneration," *Expert Opinion on Therapeutic Targets* 11 (2007): 161–179.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

Sclerosis," *Journal of Neuroscience* 28 (2008): 13574–13581.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

180 H. E. de Vries, M. Witte, D. Hondius, et al., "Nrf2-Induced Antioxidant Protection: A Promising Target to Counteract ROS-Mediated Damage in Neurodegenerative Disease?," *Free Radical Biology and Medicine* 45 (2008): 1375–1383.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

181 T. Perry, H. W. Holloway, A. Weerasuriya, et al., "Evidence of GLP-1-Mediated Neuroprotection in an Animal Model of Pyridoxine-Induced Peripheral Sensory Neuropathy," *Experimental Neurology* 203 (2007): 293–301.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

182 C. Hölscher, "The Role of GLP-1 in Neuronal Activity and Neurodegeneration," *Vitamins & Hormones* 84 (2010): 331.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

183 Y. Li, T. Perry, M. S. Kindy, et al., "GLP-1 Receptor Stimulation Preserves Primary Cortical and Dopaminergic Neurons in Cellular and Rodent Models of Stroke and Parkinsonism," *Proceedings of the National Academy of Sciences of the United States of America* 106 (2009): 1285–1290.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

184 S. G. Kennedy, E. S. Kandel, T. K. Cross, and N. Hay, "Akt/Protein Kinase B Inhibits Cell Death by Preventing the Release of Cytochrome c From Mitochondria," *Molecular and Cellular Biology* 19 (1999): 5800–5810.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

185 A. Brunet, S. R. Datta, and M. E. Greenberg, "Transcription-Dependent and -Independent Control of Neuronal Survival by the PI3K–Akt Signaling Pathway," *Current Opinion in Neurobiology* 11 (2001): 297–305.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

(2008): 146–150.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

187 T. Mantamadiotis, T. Lemberger, S. C. Bleckmann, et al., “Disruption of CREB Function in Brain Leads to Neurodegeneration,” *Nature Genetics* 31 (2002): 47–54.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

188 M. Dragunow, “CREB and Neurodegeneration,” *Frontiers in Bioscience* 9 (2004): 100.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

189 K. F. Schulz, D. G. Altman, and D. Moher, “CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials,” *Journal of Pharmacology and Pharmacotherapeutics* 1 (2010): 100–107.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

190 R. B. Silverman and M. W. Holladay, *The Organic Chemistry of Drug Design and Drug Action* (Academic Press, 2014).

[Google Scholar](#)

191 M. Imenshahidi and H. Hosseinzadeh, “Berberine and Barberry (*Berberis vulgaris*): A Clinical Review,” *Phytotherapy Research* 33 (2019): 504–523.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

192 F.-Q. Zhu, L. Chen, and J.-H. Zhu, “Influence of Berberine Combining With Atorvastatin on Serum High-Sensitivity C-Reactive Protein and Adipocyte Fatty Acid-Binding Protein in Patients With Acute Ischemic Stroke,” *Chinese Journal of Contemporary Neurology & Neurosurgery* 15 (2015): 43.

[Google Scholar](#)

Blind, Randomized, Parallel-Controlled Study,” *Genome Medicine* 13 (2021): 125.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

194 Y. Li, P. Wang, M.-J. Chai, et al., “Effects of Berberine on Serum Inflammatory Factors and Carotid Atherosclerotic Plaques in Patients With Acute Cerebral Ischemic Stroke,” *China Journal of Chinese Materia Medica* 41 (2016): 4066.

[PubMed](#) | [Google Scholar](#)

195 S. A. Soudi, M. I. Nounou, S. A. Sheweita, D. A. Ghareeb, L. K. Younis, and L. K. El-Khordagui, “Protective Effect of Surface-Modified Berberine Nanoparticles Against LPS-Induced Neurodegenerative Changes: A Preclinical Study,” *Drug Delivery and Translational Research* 9 (2019): 906–919.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

196 F. Zhu and C. Qian, “Berberine Chloride Can Ameliorate the Spatial Memory Impairment and Increase the Expression of Interleukin-1beta and Inducible Nitric Oxide Synthase in the Rat Model of Alzheimer's Disease,” *BMC Neuroscience* 7 (2006): 78.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

197 L. Huang, Z. Luo, F. He, A. Shi, F. Qin, and X. Li, “Berberine Derivatives, With Substituted Amino Groups Linked at the 9-Position, as Inhibitors of Acetylcholinesterase/Butyrylcholinesterase,” *Bioorganic & Medicinal Chemistry Letters* 20 (2010): 6649.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

198 P. Riederer, W. Danielczyk, and E. Grünblatt, “Monoamine Oxidase-B Inhibition in Alzheimer's Disease,” *Neurotoxicology* 25 (2004): 271–277.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

199 L. D. Kong, C. H. Cheng, and R. X. Tan, “Monoamine Oxidase Inhibitors From Rhizoma of *Coptis chinensis*,” *Planta Medica* 67 (2001): 74–76.

200 X. Y. Xu, H. G. Ding, W. G. Li, et al., "Chinese Guidelines on Management of Hepatic Encephalopathy in Cirrhosis," *World journal of gastroenterology* **25**, no. 36 (2019): 5403.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

201 J. Li, Y. Zhao, Y. Liu, et al., "The Impact of Berberine on Insulin Resistance and Cytokines in Patients With Schizophrenia," *Tianjin Medical Journal* **44** (2016): 1143.

[Google Scholar](#)

202 L. Dan, Y. Hao, J. Li, et al., "Neuroprotective Effects and Possible Mechanisms of Berberine in Animal Models of Alzheimer's Disease: A Systematic Review and Meta-Analysis," *Frontiers in Pharmacology* **14** (2024): 1287750.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

203 J.-Y. Liu, Y. Dai, Y.-X. He, and L. Lin, "Effect of Berberine on Cognitive Function and β -Amyloid Precursor Protein in Alzheimer's Disease Models: A Systematic Review and Meta-Analysis," *Frontiers in Pharmacology* **14** (2024): 1301102.

[PubMed](#) | [Google Scholar](#)

204 D. Luo, B. Yu, S. Sun, et al., "Effects of Adjuvant Berberine Therapy on Acute Ischemic Stroke: A Meta-Analysis," *Phytotherapy Research* **37** (2023): 3820–3838.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

205 M. Imenshahidi and H. Hosseinzadeh, "***Berberis vulgaris*** and Berberine: An Update Review," *Phytotherapy Research* **30** (2016): 1745–1764.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

206 L. Baaxin, Y. Baofeng, and H. Xiaomin, "Study on the Pharmacokinetics of Berberine in Single Dosage and Coadministration With Oryzanol in Rabbits and Healthy Volunteers," *Chinese Pharmaceutical Journal-Beijing* **35** (2000): 33.

[Google Scholar](#)

the Treatment of Primary Dysmenorrhea,” *Frontiers in Pharmacology* 13 (2022): 942955.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

208 Q. Xiong, S. Kadota, T. Tani, and T. Namba, “Antioxidative Effects of Phenylethanoids From *Cistanche Deserticola*,” *Biological and Pharmaceutical Bulletin* 19, no. 12 (1996): 1580–1585.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

209 J.-F. Pan, C. Yu, D.-Y. Zhu, et al., “Identification of Three Sulfate-Conjugated Metabolites of Berberine Chloride in Healthy Volunteers' Urine After Oral Administration,” *Acta Pharmacologica Sinica* 23 (2002): 77–82.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

210 W. Chen, Y.-Q. Miao, D.-J. Fan, et al., “Bioavailability Study of Berberine and the Enhancing Effects of TPGS on Intestinal Absorption in Rats,” *Aaps Pharmscitech* 12 (2011): 705–711.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

211 C.-S. Liu, Y.-R. Zheng, Y.-F. Zhang, and X.-Y. Long, “Research Progress on Berberine With a Special Focus on Its Oral Bioavailability,” *Fitoterapia* 109 (2016): 274–282.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

212 M. M. Kheir, Y. Wang, L. Hua, et al., “Acute Toxicity of Berberine and Its Correlation With the Blood Concentration in Mice,” *Food and Chemical Toxicology* 48 (2010): 1105–1110.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

213 A. Terpstra, “Differences Between Humans and Mice in Efficacy of the Body Fat Lowering Effect of Conjugated Linoleic Acid: Role of Metabolic Rate,” *Journal of Nutrition* 131 (2001): 2067–2068.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

215 W. Hua, L. Ding, Y. Chen, B. Gong, J. He, and G. Xu, "Determination of Berberine in Human Plasma by Liquid Chromatography–Electrospray Ionization–Mass Spectrometry," *Journal of Pharmaceutical and Biomedical Analysis* 44 (2007): 931–937.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

216 S. Spinozzi, C. Colliva, C. Camborata, et al., "Berberine and Its Metabolites: Relationship Between Physicochemical Properties and Plasma Levels After Administration to Human Subjects," *Journal of Natural Products* 77 (2014): 766–772.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

217 Y.-T. Liu, H.-P. Hao, H.-G. Xie, et al., "Extensive Intestinal First-Pass Elimination and Predominant Hepatic Distribution of Berberine Explain Its Low Plasma Levels in Rats," *Drug Metabolism and Disposition* 38 (2010): 1779–1784.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

218 X. Zhang, F. Qiu, J. Jiang, C. Gao, and Y. Tan, "Intestinal Absorption Mechanisms of Berberine, Palmatine, Jateorhizine, and Coptisine: Involvement of P-Glycoprotein," *Xenobiotica* 41 (2011): 290–296.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

219 G. Y. Pan, G. J. Wang, X. D. Liu, J. P. Fawcett, and Y. Y. Xie, "The Involvement of P-Glycoprotein in Berberine Absorption," *Pharmacology & Toxicology* 91 (2002): 193.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

220 K. Wang, X. Feng, L. Chai, S. Cao, and F. Qiu, "The Metabolism of Berberine and Its Contribution to the Pharmacological Effects," *Drug Metabolism Reviews* 49 (2017): 139–157.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

222 Y. Guo, C. Pope, X. Cheng, H. Zhou, and C. D. Klaassen, "Dose–Response of Berberine on Hepatic Cytochromes P450 mRNA Expression and Activities in Mice," *Journal of Ethnopharmacology* **138** (2011): 111–118.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

223 J. Yi, X. Ye, D. Wang, et al., "Safety Evaluation of Main Alkaloids From Rhizoma Coptidis," *Journal of Ethnopharmacology* **145** (2013): 303–310.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

224 F. Di Pierro, N. Villanova, F. Agostini, R. Marzocchi, V. Soverini, and G. Marchesini, "Pilot Study on the Additive Effects of Berberine and Oral Type 2 Diabetes Agents for Patients With Suboptimal Glycemic Control," *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy* **5** (2012): 213.

[CAS](#) | [PubMed](#) | [Google Scholar](#)

225 N. Singh and B. Sharma, "Toxicological Effects of Berberine and Sanguinarine," *Frontiers in Molecular Biosciences* **5** (2018): 21.

[PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

226 A. Phogat, J. Singh, V. Malik, and V. Kumar, "Neuroprotective Potential of Berberine Against Acetaminophen Induced Toxicity in Rats: Implication of Oxidative Stress, Mitochondrial Alterations, and Structural Changes in Brain Regions," *Journal of Biochemical and Molecular Toxicology* **37** (2023): e23434.

[CAS](#) | [PubMed](#) | [Web of Science®](#) | [Google Scholar](#)

Research Technician

- Chapel Hill, NC
- University of North Carolina at Chapel Hill

Undergraduate Student Assistant

- University of Kansas Lawrence Campus
- The University of Kansas

Dean, College of Food, Agricultural and Natural Resource Sciences and Director, MAES

- Competitive
- Saint Paul, Minnesota
- University of Minnesota

Senior Scientist Postdoctoral, Psychology

Jobs shared from the **Wiley Career Network**

[Download PDF](#)

ABOUT WILEY ONLINE LIBRARY

[Privacy Policy](#)

[Terms of Use](#)

[About Cookies](#)

[Manage Cookies](#)

[Accessibility](#)

[Wiley Research DE&I Statement and Publishing Policies](#)

HELP & SUPPORT

[Contact Us](#)

[Training and Support](#)

[DMCA & Reporting Piracy](#)

[Sitemap](#)

OPPORTUNITIES

[Subscription Agents](#)

[Advertisers & Corporate Partners](#)

CONNECT WITH WILEY

[< Back](#)

Copyright © 1999-2026 John Wiley & Sons, Inc or related companies. All rights reserved, including rights for text and data mining and training of artificial intelligence technologies or similar technologies.